NIDDK Is Putting $12 Million Into Type 1 Diabetes Research That Runs on Human Models, Not Animals
November 16, 2026 · 6 min read
Granted Research Team · Editorial policy
Academic PIs and NIH-funded investigators in type 1 diabetes biology now have a dated target: NIDDK's forecast for RFA-DK-28-113, posted to grants.gov on November 5, puts $12 million behind 12 cooperative agreements that must run on human-relevant models, with applications estimated due February 10, 2027.
What NIDDK put on the forecast board on November 5
The record went up at grants.gov opportunity 364219 on November 5, 2026, under the title "Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)." It is a forecast, not a live solicitation — NIDDK estimates the synopsis posts December 1, 2026, which is when the full NOFO text, review criteria, and page limits become readable.
That distinction matters more than it sounds. A forecast is the only window in which a PI can assemble a team, negotiate tissue access, and run pilot data before the clock starts. If the estimated dates hold, applications are due February 10, 2027 — roughly ten weeks after the synopsis appears. Teams that wait for the full announcement to start thinking will be writing a multi-site cooperative agreement in under three months.
The numbers on the forecast are specific. NIDDK estimates $12,000,000 in total funding across 12 anticipated awards — about $1 million per award — with no cost sharing required. The instrument is a cooperative agreement, the activity code is U01, and clinical trials are not allowed. Estimated award date is October 1, 2027, with projects starting November 1, 2027 against fiscal year 2028 money. The administrative contact is NIDDK's Division of Digestive Diseases and Nutrition at NIDDK_DEM@nih.gov.
Eligibility is wide: public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with and without 501(c)(3) status, small businesses, other for-profits, tribal governments and organizations, state and local governments, and — notably — non-domestic entities, meaning foreign institutions can apply. For a program built on access to scarce human pancreatic tissue, opening the door to international biobanks and consortia is not a throwaway clause.
The RFA is written around human models, not against animal ones
The forecast description is unusually direct about method. The NOFO "will support research using human-relevant New Approach Methodologies (NAMs) to advance understanding of the earliest events that initiate and drive Type 1 Diabetes (T1D)." Projects are expected to use "human cells and tissues and innovative experimental and computational approaches–including organoids, microphysiological systems, and other advanced human-relevant models–to investigate cellular and molecular mechanisms involved in T1D initiation and early disease progression."
The scientific target is narrower than "study T1D." NIDDK wants work aimed at the window before the damage is done: research "expected to identify and validate early biomarkers and therapeutic targets and advance new strategies to prevent or interrupt disease progression before substantial pancreatic beta cell loss occurs." That phrasing rules a lot of otherwise excellent science out of scope. A project that characterizes established disease, or that reads out beta cell function in an end-stage model, is not what this RFA is buying. The responsive application studies initiation and early progression, in human material, with a path to a biomarker or a target.
This is the first NIDDK T1D RFA that makes NAMs the organizing premise rather than an allowable alternative — and it lands in the middle of a visible NIH-wide methods shift. In March 2026, NIH announced more than $150 million in first awards under Complement Animal Research In Experimentation (Complement-ARIE), a Common Fund program to "develop and scale research methods that better simulate human biology and reduce reliance on animal models." Nicole Kleinstreuer, NIH Deputy Director for Program Coordination, Planning, and Strategic Initiatives, framed the spend as core rather than peripheral: "NIH's investment in NAMs is critical to our mission to carry out gold-standard research." Alongside the awards, NIH put $7 million in prizes behind a NAMs Reduction to Practice Challenge and signaled roughly $20 million toward a Validation and Qualification Network, pending available funds.
What RFA-DK-28-113 shows is that shift moving from the Common Fund into the institutes' own disease portfolios. Complement-ARIE builds and validates the methods; this RFA spends an institute's categorical money applying them to a specific disease mechanism. PIs tracking the policy only through Common Fund announcements have been watching the wrong surface.
Joining HIRN is a condition of the award, not a perk
The second half of the forecast description is where the real structural obligation sits. "Funded projects will become part of the Human Islet Research Network (HIRN)," and awardees "will be expected to participate in collaborative activities, share tools and data, coordinate the use of scarce human pancreatic tissues, and promote harmonization and interoperability of approaches and datasets where appropriate."
HIRN is not new. NIDDK established it in 2014 as a modular, team-science network of small consortia plus an administrative hub — a Coordinating Center and a Bioinformatics Center, both funded through U01 cooperative agreements held at City of Hope. The network has been rebuilt repeatedly through targeted RFAs: the Human Pancreas Analysis Consortium came in through RFA-DK-17-022, the Consortium on Targeting and Regeneration was reissued under RFA-DK-22-009, and the Consortium on Beta Cell Death and Survival was funded under RFA-DK-23-007, now expired. Read against that history, RFA-DK-28-113 looks less like a one-off and more like the next consortium slot — this time defined by methodology rather than by biological process.
For application strategy, that changes what reviewers will weight. A U01 with mandatory network membership is scored partly on whether the applicant can actually function inside a consortium: data standards, shared protocols, a tissue-allocation plan that does not assume the applicant gets first call on every donor pancreas. The single-lab proposal that would do well as an R01 tends to do badly here. The forecast says plainly that the point is "to overcome barriers that have limited progress by individual laboratories." Teams should budget real effort for coordination and name the interoperability commitments explicitly rather than gesturing at collaboration in a resource-sharing boilerplate paragraph.
Two assistance listings suggest more than one institute at the table
A detail worth flagging: the forecast carries two CFDA assistance listings — 93.KRP, "Diabetes, Digestive, Kidney Extramural Research — Research Projects," which is the expected NIDDK line, and 93.855, "Allergy and Infectious Diseases Research," which is NIAID's. For an autoimmune disease RFA focused on disease triggers, a NIAID listing is a plausible co-funding or co-interest signal rather than a clerical accident. It is not confirmation of a partnership, and the synopsis on December 1 is where any participating-institute language will appear. But applicants with immunology as well as islet biology on the team have a reason to watch for it.
The real deadline is December 1, not February 10
Forecast dates slip. The useful way to read this record is as a two-stage schedule: the synopsis target of December 1, 2026 is the date that determines whether the February 10, 2027 receipt date is realistic, and the receipt date is the one that governs whether a team can be assembled in time. Work back from February 10 and the hard items are not the Research Strategy — they are the letters of support from tissue sources, the multi-PI leadership plan, and the data-sharing architecture that a network award will be judged on.
PIs who have been through an NIH mechanism reshuffle recently will recognize the pattern of a shifting portfolio being announced in pieces. The same dynamic is playing out on the career-development side, where NIH is collapsing 14 K awards into four and retiring the independent clinical trial K. In both cases the announcement that matters is the one with a date attached, and the window between the forecast and the receipt date is where the real work gets done.
For this RFA, the specific preparation is unglamorous and time-consuming. Confirm now whether your human islet, organoid, or microphysiological platform can produce the early-initiation readouts the RFA asks for, or whether you need a partner who can. Identify who on your team can speak to validation and interoperability, because a NAMs-premised award will be reviewed by people asking whether the model is fit for purpose. And if you intend to apply as a foreign institution or with an international tissue source, start the subaward and material transfer paperwork before December, not after.
Find the T1D and NAMs opportunities already open
RFA-DK-28-113 will not accept applications until the synopsis posts. In the meantime, the overlapping programs — NIDDK islet biology awards, Complement-ARIE-adjacent methods funding, and autoimmune mechanism RFAs — are findable now. Search active type 1 diabetes funding opportunities on Granted to see what is open with a nearer deadline, and track the November 5 forecast record so you are drafting on December 1 rather than reading.